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ABSTRACT
A simple, reliable, rapid, precise, sensitive and validated RP-HPLC method has been developed to determine Aspirin and 
Prasugrel in synthetic mixture form. Chromatographic separation achieved isocratically on Luna C18 column (5µm, 150mm 
× 4.60mm) and acetonitrile: 0.05M ammonium acetate buffer (pH 4.5) in the ratio of 75:25 (v/v) as the mobile phase, at a 
flow rate of 0.6 ml/min. Detection was carried out at 245 nm. Parameters such as linearity, precision, accuracy, recovery, 
specificity and ruggedness are studied as reported in the ICH guidelines. The retention times for Aspirin and Prasugrel was 
found to be 2.25±0.5 and 8.72±0.5 min respectively. Linearity for Aspirin and Prasugrel was in the range of 75-375μg/ml
and 10-50μg/ml respectively.  The mean recoveries obtained for Aspirin and Prasugrel were 99.58 and 99.48 % respectively 
and RSD was less than 2. The correlation coefficients for all components are close to 1. Developed method was found to be 
accurate, precise, selective and rapid for simultaneous estimation of Aspirin and Prasugrel.
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INTRODUCTION
Aspirin (ASP), 2-acetoxy benzoic acid [Figure 1A] is cyclo 
oxygenase inhibitor. It is used as an analgesic, antipyretic, 
anti-inflammatory and anti thrombic agent.
[1] It is one of the 
most widely used anionic drugs in the world. Once ingested, 
aspirin is rapidly hydrolyzed in the body to produce salicylic 
acid, which is the compound that is primarily responsible for 
the pharmacological activity of aspirin.
[2] Aspirin is official 
in  IP 
[3],  BP 
[4] and  USP.
[5]  Several  methods  have  been 
employed for the estimation of aspirin alone and combination 
with other drugs such as UV,
[6-7] RP-HPLC,
[8-19] HPTLC,
[20-21] 
spectrofluorometric, 
[22] spectrometric  method.
[23-24] A 
number  of  acute  coronary  syndrome  (ACS)  trials  have 
demonstrated  significant  regional  variation  in  clinical 
outcomes and treatment effects.
[25-27] 
Dual anti-platelet therapy with aspirin and a thienopyridine is 
a  cornerstone  of  treatment  to  prevent  thrombotic 
complications  of  ACS  and  percutaneous  coronary 
intervention (PCI).
[28-29] In the trial to assess improvement in 
therapeutic outcomes by optimizing platelet inhibition with 
prasugrel-thrombolysis  in  myocardial  infarction  38 
(TRITON-TIMI 38), more intensive and consistent anti-
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platelet  therapy  with  the  third-generation thienopyridine 
prasugrel resulted in a reduction in ischemic events, increase 
in  bleeding  and  on  balance,  an  improved  net  clinical 
outcome.
[30] Prasugrel (PRA) chemically  is  5-[2-
cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,  5,  6,  7-tetra 
hydrothieno [3, 2- c] pyridin-2-yl acetate [Figure 1B]. It is a 
member  of  the  thienopyridine  class  of  ADP  receptor 
inhibitors,  like  ticlopidine  and  clopidogrel.  These  agents 
reduce  the  aggregation  (“clumping”)  of  platelets  by 
irreversibly  binding  to  P2Y12  receptors.  Prasugrel  inhibits 
adenosine  diphosphate-induced  platelet  aggregation  more 
rapidly,  more  consistently  and  to  a  greater  extent  than  do 
standard  and  higher  doses  of  clopidogrel  in  healthy 
volunteers  and  in  patients  with  coronary  artery  disease. 
Literature survey revealed that only a few analytical methods 
such  as  UV,
[31-32] HPLC, 
[33-34] LC-MS, 
[35-37] HPTLC 
[38]
have been reported. 
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Fig. 1: Chemical structures of (A) Aspirin (B) Prasugrel
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and PRA. In the present work we are therefore focused on to 
achieve  the  optimum  chromatographic  conditions  for  the 
simultaneous determination of ASP and PRA in a synthetic 
mixture.  We describe in this paper a simple, sensitive and 
validated  HPLC  method  with  total  run  time  less  than  9 
minutes for the simultaneous determination of ASP and PRA. 
The developed method can be applied successfully to quality 
control  and  for  other  analytical  purposes.  To  access  the 
reproducibility  and  wide  applicability  of  the  developed 
method, it was validated as per ICH guidelines 
[39-40], which 
is mandatory also.
MATERIALS AND METHODS
Instrumentation
Liquid chromatographic system from Shimadzu (LC-20AT) 
comprising of manual injector, double reciprocating plunger 
pump LC-20ATVp for constant flow and constant pressure 
delivery  and  Photodiode  array  detector  SPD-M20A 
connected  to  software  LC  solution  for  controlling  the 
instrumentation as well as processing the data generated was 
used.
Chemicals and reagents
Analytically pure sample of ASP was a generous gift from 
Lupin Laboratories Mumbai, India and PRA was an obtained 
from Aurbindo Pharma Ltd., Hyderabad. Ammonium acetate, 
glacial  acetic  acid  and  acetonitrile  (HPLC  Grade)  was 
purchased from E. Merck  Ltd. Worli,  Mumbai, India.  The 
0.45µm nylon filters were purchased from Advanced Micro 
Devices  Pvt.  Ltd.  Chandigadh,  India.  All  excepients  used 
were  of  pharmaceutical  grade.  Triple  distilled  water  was 
generated in house. 
Chromatographic conditions
The isocratic mobile phase consisted of acetonitrile: 0.05M 
ammonium acetate buffer (pH 4.5) in the ratio of 75:25 (v/v), 
flowing through  the column  at a constant  flow rate  of 0.6 
ml/min. A Luna C18 column (5 µm, 150mm × 4.60mm) was 
used  as  the  stationary  phase.  By  considering  the 
chromatographic  parameter,  sensitivity  and  selectivity  of 
method for two drugs, 245nm was selected as the detection 
wavelength  for  UV-PDA  detector.  The  HPLC  system  was 
operated at room temperature 25°C.
Standard preparation
Standard stock solution 
Standard  stock  solutions  were  prepared  by dissolving 
separately 100 mg of each drug in 100 ml of diluent which 
was a mixture of acetonitrile and ammonium acetate buffer in 
the ratio of 50:50 (pH 4.5) to get concentration of 1000μg/ml.
Working standard solution 
Working  standard  solutions  were  prepared  by  taking 
dilutions ranging from 75-375, 10-50μg/ml for ASP and PRA 
respectively.
Sample preparation 
The  content  of  twenty  tablets  where  taken  and  weighed. 
Powdered equivalent to 300mg aspirin and 10 mg prasugrel 
was dissolved in 100ml diluents and then sonicated for 15
min.  and  filtered  through  watmann  paper  no.  41.    Then 
different  concentration  of  solution  were  prepared  by  serial 
dilution  technique,  as  per  standard  and  each  dilution  was 
analysed.
RESULTS AND DISCUSSION
Chromatography
The  mobile  phase  was  chosen  after  several  trials  with 
methanol,  isopropyl  alcohol,  acetonitrile,  water  and  buffer 
solutions in various proportions and at different pH values. A 
mobile  phase  consisting  of  acetonitrile:  0.05M  ammonium 
acetate buffer (75:25, v/v, pH 4.5) was selected to achieve 
maximum separation and sensitivity. Flow rates between 0.5 
and 1.5 ml/ml were studied. A flow rate of 0.6 ml/ml gave an 
optimal  signal  to  noise  ratio  with  a  reasonable  separation 
time. Using a reversed-phase C18 column, the retention times 
for ASP and PRA were observed to be 2.25±0.5 and 8.72±0.5 
min respectively. Total time of analysis was less than 9 min. 
The  maximum  absorption  of  ASP  and  PRA  together  as 
detected at 245 nm and this wavelength was chosen for the 
analysis Fig. 2. 
System suitability
System suitability parameters such as number of theoretical 
plates,  HETP  and  peak  tailing  are  determined.  The  results 
obtained are  shown  in  Table 1.  The  number  of  theoretical 
plates for ASP and PRA were1543 and 9261 respectively.
Linearity
The calibration curve was linear over the concentration range 
of 75-375μg/ml for ASP and 10-50μg/ml for PRA.
Table 1: System suitability parameters
Parameter Aspirin Prasugrel
Retention time* 2.25 ± 0.5 8.72 ± 0.5
No. of theoretical plate* 1543.26±26.29 9261.33±16.72
Tailing factor* 0.89±0.01 0.98±0.01
HETP* 0.16±0.01 0.027±0.02
Calibration Range 75-375 g/ml 10-50 g/ml
* Each value is the Mean ± S.D of six determinations
Table 2: Result of recovery studies with statically evaluation
S. 
No
Conc. of 
drug in 
preanalyzed 
samples 
(g/ml)
Std. drug 
sol. Added 
(g/ml)
Recovered 
amount*
(g/ml)
% Recovered
ASP PRA ASP PRA ASP PRA ASP PRA
1 150 20 120 16 266.78 36.03 98.80 100.08
2 150 20 150 20 300.05 39.45 100.01 98.62
3 150 20 180 24 329.85 43.89 99.95 99.75
Mean 99.58 99.48
S.D 0.063 0.467
%R.S.D 0.063 0.469
* Mean of Nine determinations (3 replicates at 3 concentration level)
Table 3: Result of precision and robustness
Validation 
Parameter
Percentage Mean ± 
S.D*(n=15) Percentage RSD*
ASP PRA ASP PRA
Repeatability 98.23±1.12 99.02±1.41 98.74±1.46 98.63±1.25
Intermediate 
precision
Day to Day 97.96±0.21 98.34±0.55 98.01±1.68 97.67±1.29
Analyst to 
Analyst
98.29±0.56 98.75±0.53 99.07±1.06 98.43±1.01
Reproducibility 99.03±0.42 99.31±0.24 98.72±0.23 99.08±1.06
Robustness 98.61±0.06 99.46±0.87 98.22±0.27 98.75±1.08
Table 4: Stability data of ASP and PRA
Hours ASP PRA
0 746489 239584
6 748652 243565
12 751234 246854
Table 5: Statistical evaluation of synthetic mixture analysis
Parameter
Sample
ASP PRA
Mean % estimated 98.61 98.1
Standard deviation(S.D.) 0.45 0.12
% Coefficient of variation 0.456 0.122
*Standard error (SEσ) 0.106 0.028
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Fig. 2: Chromatograms of ASP (150g/ml) and PRA (20g/ml) reference substance
Fig. 3: Chromatograms of ASP (300g/ml) and PRA (40g/ml) in a synthetic mixture
The linearity was represented by a linear regression equation 
as follows.
Y (ASP) = 11420.56conc. – 65319.14 (r
2=0.998)
Y (PRA) = 28537.15conc. -11811.28 (r
2=0.999)
Where Y is area under curve and r
2 is correlation coefficient.
Accuracy
Method accuracy was performed by adding known amounts 
of  ASP  and  PRA  to  the  pre-analysed  synthetic  mixture 
solution and then comparing the added concentration with the 
found  concentration.  Three  levels  of  solutions  were  made 
which  correspond  to  80,  100  and  120  %  of  the  nominal 
analytical concentration (150μg/ml for ASP and 20μg/ml for 
PRA). Each level was made in triplicate Table 2. The mean 
percentage recoveries obtained for ASP and PRA were 99.58 
and 99.48 % respectively and RSD was less than 2.
Repeatability
Five dilutions in three replicates were analyzed in same day 
for  repeatability  and  results  were  found  within  acceptable 
limits (RSD ‹ 2) as shown in Table 3.
Intermediate Precision
Five  dilutions  in  three  replicates  were  analyzed  on  two 
different days and by two analysts for day to day and analyst 
to analyst variation and results were found within acceptable 
limits (RSD ‹ 2) as shown in Table 3.
Robustness
As  per  ICH  norms,  small,  but  deliberate  variations,  by 
altering the pH  or concentration of the mobile phase were 
made to check the method’s capacity to remain unaffected. 
The change was made in the ratio of mobile phase, instead of 
acetonitrile:  phosphate  buffer  (pH  4.5)  (75:25v/v), 
acetonitrile: phosphate buffer (pH 4.5) (70:30 v/v), was used 
as a mobile phase. Results of analysis were summarized in 
Table 3.
Stability of sample solution
The  sample  solution  injected  after  12  h  do  not  show  any 
appreciable change. Results are shown in Table 4.
Specificity & selectivity
Commonly  used  exceipients  (starch,  microcrystalline 
cellulose and magnesium stearate, lactose,) were spiked in to 
a  pre  weighed  quantity  of  drugs  .The  chromatogram  was 
taken by appropriate dilution and the quantities of drug were 
determined.  The  specificity  of  the  HPLC  method  is 
illustrated  in  Fig. 3.  Where  complete  separation  of aspirin 
and prasugrel in presence of tablet excipients.
Synthetic mixture analysis
Content of ASP and PRA found in the synthetic mixture by 
the proposed method are shown in Table 5. The low values of 
R.S.D. indicate that the method is precise and accurate.
A  simple  precise,  reliable,  rapid,  sensitive  and  accurate 
reverse  phase  HPLC  method  has  been  developed  for  the 
simultaneous  determination  of  aspirin  and  prasugrel.  The 
developed  method  is  suitable  for  the  identification  and 
quantification of binary combination of aspirin and prasugrel. 
A high percentage of recovery and the run time of less than 
nine  minutes  allow  its  application  for  the  routine 
determination of aspirin and prasugrel in tablet dosage form.
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